Abstract
This Practice Point commentary discusses the paper by Horwitz and colleagues, which reported the long-term results of the RTOG 92-02 trial in which patients with locally advanced, node-negative prostate cancer who were treated with neoadjuvant–concurrent hormone ablation therapy and external beam radiation therapy (70 Gy) were subsequently randomized to receive either no further androgen deprivation or long-term (2-year) goserelin therapy. The results at 10 years confirm biochemical and clinical outcome benefits with the use of long-term androgen deprivation therapy for patients treated with conventional-dose radiotherapy. How these results should best be incorporated into dose-escalated radiotherapeutic approaches remains unclear, however, and this issue requires further investigation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Horwitz EM et al. (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26: 2497–2504
Valicenti RK et al. (2007) Does adjuvant hormonal therapy improve freedom from biochemical relapse in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of RTOG 94-06 [abstract]. Int J Radiat Oncol Biol Phys 69 (3 Suppl 1): S171
Dearnaly DP et al. (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8: 475–487
Martinez A et al. (2003) No apparent benefit at five years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with high total radiation dose. J Urol 170: 2296–2301
Merrick GS et al. (2007) Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 68: 34–40
Zelefsky MJ et al. (2008) Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 53: 1172–1179
Bolla M et al. (2007) Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—results of the randomized EORTC Phase III trial 22961 [abstract]. J Clin Oncol 25 (18 Suppl): 5014–5015
Efstathiou JA Shipley et al. (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol [10.1016/j.eururo.2008.01.021]
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kollmeier, M., Zelefsky, M. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?. Nat Rev Urol 5, 584–585 (2008). https://doi.org/10.1038/ncpuro1217
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1217
